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Hyperglycemia-Induced Reactive Oxygen Species Increase
Expression of the Receptor for Advanced Glycation End
Products (RAGE) and RAGE Ligands
Dachun Yao and Michael Brownlee
OBJECTIVE—RAGE interacts with the endogenous ligands
S100 calgranulins and high mobility group box 1 (HMGB1) to
induce inﬂammation. Since hyperglycemia-induced reactive ox-
ygen species (ROS) activate many pathways of diabetic tissue
damage, the effect of these ROS on RAGE and RAGE ligand
expression was evaluated.
RESEARCH DESIGN AND METHODS—Expression of RAGE,
S100A8, S100A12, and HMGB1 was evaluated in human aortic
endothelial cells (HAECs) incubated in normal glucose, high
glucose, and high glucose after overexpression of either uncou-
pling protein 1 (UCP1), superoxide dismutase 2 (SOD2), or
glyoxalase 1 (GLO1). Expression was also evaluated in normal
glucose after knockdown of GLO1. Expression was next
evaluated in high glucose after knockdown of nuclear factor
(NF)-B p65 (RAGE) and after knockdown of activated pro-
tein-1 (AP-1) (S100A8, S100A12, and HMGB1), and chromatin
immunoprecipitation (ChIP) was performed  GLO1 overex-
pression for NFB p65 (RAGE promoter) and AP-1 (S100A8,
S100A12, and HMGB1 promoters). Finally, endothelial cells from
nondiabetic mice, STZ diabetic mice, and STZ diabetic mice
treated with the superoxide dismutase mimetic Mn(III)tet-
rakis(4-benzoic acid)porphyrin chloride (MnTBAP) were
evaluated.
RESULTS—High glucose increased RAGE, S100A8, S100A12,
and HMGB1 expression, which was normalized by overexpres-
sion of UCP1, SOD2, or GLO1. GLO1 knockdown mimicked the
effect of high glucose, and in high glucose, overexpression of
GLO1 normalized increased binding of NFB p65 and AP-1.
Diabetes increased RAGE, S100A8, and HMGB1 expression, and
MnTBAP treatment normalized this.
CONCLUSIONS—These results show that hyperglycemia-in-
duced ROS production increases expression of RAGE and RAGE
ligands. This effect is mediated by ROS-induced methylglyoxal,
the major substrate of glyoxalase 1. Diabetes 59:249–255, 2010
T
he receptor for advanced glycation end products
(RAGE) is a pattern recognition receptor that
interacts with a number of endogenous ligands
in normal physiology, playing a homeostatic role
in lung development, osteoclast differentiation, innate
immunity, and inﬂammatory cell recruitment and adhesion
(1–3). However, conditions such as diabetes disturb ho-
meostasis, increase RAGE expression (4), increase ad-
vanced glycation end product formation, and cause
release of intracellular calcium binding molecules, the
S100 calgranulins (5–7), and the DNA binding protein
amphoterin, or high mobility group box 1 (HMGB1), which
act as danger signals, called alarmins, that bind to RAGE
with high afﬁnity and activate immune cells and vascular
endothelium (1,8,9). RAGE signaling stimulates a host of
proinﬂammatory events (1,3). Normally, these appear to
play an important role in acute inﬂammation. In contrast,
when responding to persistent elevations of endogenous
ligands, RAGE signaling promotes chronic inﬂammation.
Such chronic inﬂammation plays a major role in the
development of diabetic complications, including athero-
sclerosis (10–12).
Because hyperglycemia-induced reactive oxygen spe-
cies (ROS) activate many pathways of diabetic tissue
damage, including intracellular AGE formation (13,14), the
effect of these ROS on RAGE and RAGE ligand expression
was evaluated. Although a large number of S100 proteins
have been shown to interact with RAGE in cell-based
assays (15), S100A8 and S100A12 were selected for study
because these proteins are found in high concentrations in
inﬂamed tissue, and they exhibit proinﬂammatory effects
in vitro at concentrations found at sites of inﬂammation in
vivo (9).
RESEARCH DESIGN AND METHODS
Primary human aortic endothelial cells (HAECs) (from Cambrex) and condi-
tionally immortalized HAECs (generated by Dr. Anita Samuga, Albert Einstein
College of Medicine) were maintained in EBM-2 medium (from Lonza) with all
the supplements. Immortalized HAECs were grown at 33°C, but experiments
and treatment were performed at the nonpermissive temperature of 37°C.
Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) was obtained
from Calbiochem (San Diego, CA). UCP1, SOD2, and GLO1 cDNAs (obtained
from Open Biosystems) were cloned into the shuttle vector pAd5CMVK-NpA,
and adenoviral vectors and empty control virus were prepared by the Gene
Transfer Vector Core at the University of Iowa. Extracellular HMGB1 level
was analyzed by an HMGB1 ELISA detection kit (#APO-54N-043 from Apo-
tech) according to the manufacturer’s instructions. shRNA lentivirus for
human GLO1 and nontarget control were obtained from Sigma. GLO1 mouse
antibody was obtained from Abnova. siRNA for the nuclear factor (NF)-B p65
subunit, activated protein-1 (AP-1) (c-Jun), and scrambled oligonucleotide as
control (sc-37007) were obtained from Santa Cruz Biotech. The antibodies for
RAGE (sc-74473), S100A8 (sc-20174 for human, and sc-8113 for mouse),
HMGB1 (sc-56698), and 3-nitrotyrosine (sc-32731) were obtained from Santa
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 249Cruz Biotech. Methylglyoxal-modiﬁed protein was measured by Western
blotting using a monoclonal antibody to the major intracellular methylglyoxal-
derived epitope, N-acetyl-N (5-hydro-5-methyl)-4-imidazolone.
Measurement of ROS generation. Treated cells seeded in a 96-well plate
were incubated with 10 mol/l CM-H2DCFDA (Invitrogen) for 45 min at 37°C,
and the intracellular formation of ROS was measured at excitation/emission
wavelengths of 485/530 nm using a Wallac 1420 Fluorescent Plate Reader.
RT reaction and real-time quantitative PCR. Total RNA from cells was
extracted using the RNeasy Mini Kit or RNeasy Micro Kit (Qiagen), and the
RNA was reverse-transcribed with the SuperScript III First Strand Synthesis
System (Invitrogen). Real-time quantitative PCR (qPCR) was run on a Light-
Cycler Roche 480 with LightCycler 480 SYBR Green I Master kit (Roche). PCR
was performed by denaturing at 95°C for 7 min, followed by 45 cycles of
denaturation at 95°C, annealing at 60°C, and extension at 72°C for 10 s,
respectively. Results were normalized by -actin. Primer sequences are shown
in Table 1.
Western blotting. Proteins were separated on 10% SDS-PAGE gels, blotted
with the indicated primary antibodies, and then simultaneously incubated
with the differentially labeled species-speciﬁc secondary antibodies, anti-
RABBIT IRDye 800CW (green), and anti-MOUSE (or goat) ALEXA680 (red).
Membranes were scanned and quantitated with the ODYSSEY Infrared
Imaging System (LI-COR, Lincoln, NE).
GLO1 activity assay. GLO1 activity was measured by using a spectrophoto-
metric method that monitors the increase in absorbance at 240 nm due to the
formation of S-D-lactoylglutathione (ε 240  3.37 mmol  l
1  cm
1) for 2 min at
25°C (16). Brieﬂy, treated cells were harvested, protein lysates prepared, and
protein concentration measured by the Coomassie Protein Assay kit (Thermo
Fisher Scientiﬁc) using BSA as a standard. The reaction buffer (7.9 mmol/l
methylglyoxal, 1 mmol/l freshly prepared glutathione, and 16 mmol/l MgSO4 in
200 mmol/l imidazole buffer, pH 7.0) was incubated for at least 2 min to ensure
the equilibration of hemimercaptal, the actual substrate of GLO1. The
hemimercaptal is formed nonenzymatically and its concentration was calcu-
lated to be 0.7 mmol/l using Keq  3.1 mmol/l. The reaction was initiated by
the addition of a rate-limiting volume of protein lysates (10–30 g) to 3.0 ml
of reaction mixture. One unit of GLO1 activity is deﬁned as the amount of
enzyme catalyzing formation of 1 mol of S-D-lactoylglutathione per minute.
Chromatin immunoprecipitation (ChIP). Treated cells were washed and
cross-linked using 1% formaldehyde for 20 min. After stopping cross-linking by
addition of 0.1 mol/l glycine, cell lysates were sonicated and centrifuged. A
total of 500 g protein was precleared by BSA/salmon sperm DNA and a slurry
of protein A agarose beads. Immunoprecipitations were performed using the
indicated antibodies or preimmune rabbit IgG in the presence of BSA/salmon
sperm DNA and a 50% slurry of protein A agarose beads. Input and immuno-
precipitates were washed and eluted and then incubated for2ha t42°C in the
presence of proteinase K followed by6ha t65°C to reverse the formaldehyde
cross-linking. DNA fragments were recovered by phenol/chloroform extrac-
tion and ethanol precipitation. The related fragments on promoters of RAGE
(720 to 561), S100A8 (1,290 to 1,132), S100A12 (163 to 4), and
HMGB1 (200 to 54) were ampliﬁed by real-time PCR (qPCR).
In vivo mouse experiments. Diabetes was induced in C57/Blk6 mice by
consecutive injection of 50 mg/kg streptozotocin (STZ) (0.05 mol/l sodium
citrate, pH 5.5) for 5 days after an 8-h fast. Animals with blood glucose 300
mg/dl were considered diabetic. After 4 weeks of diabetes, one group of STZ
mice was treated with 10 mg/kg MnTBAP intraperitoneally for 7 days, whereas
control mice received only vehicle. Mice were killed by cervical dislocation,
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FIG. 1. Hyperglycemia-induced ROS increase expression of RAGE,
S100 calgranulins, and HMGB1. A: Primary HAECs were infected with
UCP1, SOD2, GLO1, or empty control adenovirus (CTL). After incuba-
tion with either low glucose (LG) (5 mmol/l) or high glucose (HG) (30
mmol/l) for 5 days, mRNA levels were determined by real-time PCR
(n  3). B: Intracellular protein levels of RAGE, S100A8, and HMGB1
were determined by Western blotting (n  4). Protein sizes were
evaluated by standard protein markers, and their sizes were as follows:
RAGE (46 kDa), S100A8 (11 kDa), and HMGB1 (25 kDa). C: Levels of
secreted HMGB1 were determined in culture medium by enzyme-linked
immunosorbent assay (ELISA) (n  5). Values are shown as means 
SD, *P < 0.05 vs. LG/CTL group. (A high-quality color digital represen-
tation of this ﬁgure is available in the online issue.)
TABLE 1
Sequences of primers
Gene Target Species Forward primer (533) Reverse primer (533 )
-actin mRNA Human gatgcagaaggagatcactgc atactcctgcttgctgatcca
RAGE mRNA Human ctaccgagtccgtgtctacca catccaagtgccagctaagag
S100A8 mRNA Human tatcaggaaaaagggtgcaga tctttgtggctttcttcatgg
S100A12 mRNA Human tctaagggtgagctgaagcag caatggctaccagggatatga
HMGB1 mRNA Human ggagatcctaagaagccgaga catggtcttccacctctctga
RAGE Promoter/ChIP Human aacatcaacactgtcccatcc ccatcacacttccaacctgtc
S100A8 Promoter/ChIP Human caaacttgccgttttccataa accacctgacacctacaagga
S100A12 Promoter/ChIP Human caggagggcaaaattcagtct ttagcccttgggtgaagaaat
HMGB1 Promoter/ChIP Human actttcacggctccaaaaa ggtttggccctgagatgtatt
-actin mRNA Mouse tcttgggtatggaatcctgtg atctccttctgcatcctgtca
vWR mRNA Mouse cctctctcaggactgcaacac tattggcagatcccactgaag
-actin mRNA Mouse tggacttcgagaatgagatgg cgcagactccataccgataaa
RAGE mRNA Mouse acatgtgtgtctgagggaagc agctctgaccgcagtgtaaag
S100A8 mRNA Mouse ccatgccctctacaagaatga tatcaccatcgcaaggaactc
HMGB1 mRNA Mouse cttcggccttcttcttgttct ggcagctttcttctcataggg
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250 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.organd the aorta was dissected and snap-frozen in OCT compound. Then, 10-m
sections were cut by microtome and mounted on PEN (polyethylene naph-
thalate) membrane slides (2.0 m, Leica). Aortic endothelial cells or smooth
muscle cells were isolated by laser capture microdissection for analysis of
mRNA expression level by qPCR. All in vivo procedures were approved by the
Institutional Animal Care and Use Committee of the Albert Einstein College of
Medicine. Blood glucose values were 158  19 mg/dl for CTL, 391  21 mg/dl
for STZ diabetic, and 376  26 mg/dl for MnTBAP-treated STZ mice. Body
weights were 29.7 	 1.7 g (CTL), 26.7 	 1.8 g (STZ), and 27.1 	 1.4 g
(MnTBAP-treated STZ mice).
Statistical analysis. Results are expressed as means  SD. All experiments
were performed at least in triplicate. Data distribution was analyzed, and
statistical differences for different treatments were evaluated by ANOVA and
the Tukey-Kramer test using SPSS 15 software.
RESULTS
In cultured HAECs, mRNA levels of RAGE, S100A8, and
S100A12 calgranulins and HMGB1 were increased by
high glucose by 2.3-, 2.1-, 3.4-, and 1.7-fold, respectively
(Fig. 1A). Each of these high glucose-induced increases
was prevented by overexpression of either uncoupling
protein-1 (UCP1) or manganese superoxide dismutase
(SOD2), both of which prevent hyperglycemia-induced
superoxide production by the mitochondrial electron
transport chain (13,14). Increased gene expression of
RAGE, S100A8, S100A12, and HMGB1 was also prevented
by overexpression of the 
-oxoaldehyde degradating en-
zyme glyoxalase 1 (GLO1). The major physiological sub-
strate for GLO1, methylglyoxal, is a highly reactive
dicarbonyl that accumulates in endothelial cells and in
several other cell types exposed to hyperglycemia, as a
consequence of increased mitochondrial superoxide pro-
duction. Overexpression of UCP1, SOD2, and GLO1 in
cells subjected to 5 mmol/l glucose decreased ROS levels
by 40% (data not shown).
Protein expression of RAGE, S100A8, and intracellular
HMGB1 paralleled mRNA levels (Fig. 1B). High glucose
increased levels 1.7-, 1.9-, and 1.5-fold, respectively. Be-
cause HMGB1 is released into the extracellular milieu
under stressed conditions (17), extracellular HMBG1 pro-
tein was also measured in the medium (Fig. 1C). Extracel-
lular HMGB1 increased 2.2-fold in high glucose. This
increase was totally normalized by overexpression of
either UCP1, or SOD2, or GLO1.
High glucose increased ROS twofold, and this was
prevented by overexpression of either UCP1, SOD2, or
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FIG. 2. Overexpression of UCP1, SOD2, and GLO1 prevents hyperglycemia-induced ROS generation and methylglyoxal formation. Primary HAECs
were infected with UCP1, SOD2, GLO1, or empty control adenovirus (CTL). After incubation with either low glucose (LG) (5 mmol/l) or high
glucose (HG) (30 mmol/l) for 1 or 5 days, the cells were used for analysis. A: ROS formation on day 5. B: Methylglyoxal-modiﬁed protein on day
5. C: Representative blots for B. D: GLO1 activity on day 1. E: GLO1 protein on day 1. F: Representative blots for E. G: GLO1 activity on day 5.
H: GLO1 protein level on day 5. I: Representative blots for H. n  4. *P < 0.05 vs. LG/CTL group. Values are shown as means  SD. (A high-quality
color digital representation of this ﬁgure is available in the online issue.)
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methylglyoxal-modiﬁed intracellular protein, and this was
also prevented by overexpression of either UCP1, SOD2,
or GLO1 (Fig. 2B). Representative Western blots are
shown in Fig. 2C. Endogenous GLO1 activity and protein
levels were unchanged after incubation in high glucose for
24 h (Fig. 2D and E). Representative Western blots for Fig.
2E are shown in Fig. 2F. However, after 5 days, hypergly-
cemia-induced ROS reduced endogenous GLO1 activity
(Fig. 2G) and protein levels (Fig. 2H) by 50%. Representa-
tive Western blots for 2 h are shown in Fig. 2I.
To conﬁrm that hyperglycemia-induced increases in
intracellular methylglyoxal were sufﬁcient to increase ex-
pression of RAGE and RAGE ligands, GLO1 was knocked
down 80% by shRNA in cells exposed to normal glucose
(Fig. 3A and B). When GLO1 was knocked down, mRNA
levels for RAGE, S100A8, S100A12, and HMGB1 were
increased by 2.3-, 1.9-, 2.4- and 1.7-fold, respectively, levels
equivalent to those induced by high glucose (Fig. 3A). In
cells incubated in high glucose, GLO1 siRNA further
increased expression of RAGE and RAGE ligands. Simi-
larly, RAGE, S100A8, and HMGB1 protein levels increased
2.1-, 1.8-, and 1.6-fold, respectively, when GLO1 was
knocked down in cells exposed to normal glucose (Fig.
3B), levels equivalent to those induced by high glucose. In
cells incubated in high glucose, GLO1 siRNA further
increased expression of RAGE and RAGE ligands. No
antibody was available for S100A12. GLO1 knockdown
also increased intracellular levels of methylglyoxal-modi-
ﬁed protein to that caused by high glucose incubation (Fig.
3C). Representative Western blots for Fig. 3C are shown in
Fig. 3D.
We next asked how ROS-induced increases in methyl-
gloxal-modiﬁed protein caused increased expression of
RAGE and its endogenous ligands. Induction of RAGE
expression by AGEs and ligands such as tumor necrosis
factor (TNF)-
 requires binding of the transcription factor
NFB (p65/p50) to canonical binding sites in the RAGE
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FIG. 3. GLO1 knockdown duplicates the effect of hyperglycemia on expression of RAGE, S100 calgranulins, and HMGB1. Conditionally
immortalized HAECs were infected with either shGLO1 or nontargeting control (CTL) lentivirus and then incubated in either low glucose (LG)
or high glucose (HG) for 5 days. A: mRNA levels were determined by real-time PCR (n  3). B: Protein levels were determine by Western blotting
(n  4). Protein sizes were evaluated and conﬁrmed by standard protein markers, and their sizes were as follows: RAGE (46 kDa), S100A8 (11
kDa), and HMGB1 (25 kDa). C: Intracellular methylglyoxal-modiﬁed proteins were quantitated by Western blotting (n  4). D: Representative
blots for C. Values are shown as means  SD. *P < 0.05 vs. CTL group. (A high-quality color digital representation of this ﬁgure is available in
the online issue.)
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ing of the transcription factor Sp1 (18,19). Because hyper-
glycemia-induced ROS cause increased expression of p65
(20), the effect of p65 knockdown by siRNA on RAGE
expression was determined. Knockdown of NFB p65
(80%) prevented increased RAGE expression by high glu-
cose (Fig. 4A). GLO1 knockdown increases p65 expression
in the absence of hyperglycemia, and GLO1 overexpres-
sion prevents high glucose-induced p65 expression (20).
Therefore, the effect of GLO1 overexpression on NFB p65
binding to the RAGE promoter was determined using
chromatin immunoprecipitation (ChIP). As shown in Fig.
4B, high glucose increased binding of this transcription
factor to the RAGE promoter, and GLO1 overexpression
prevented this. A search of the S100A8, S100A12 calgranu-
lin, and HMGB1 promoters for common putative transcrip-
tion factor binding sites showed that binding sites for the
redox-sensitive transcription factor AP-1 were common to
all three promoters. Therefore, the effect of AP-1 (c-jun)
knockdown by siRNA on RAGE expression was deter-
mined. Knockdown of AP-1 prevented increased S100A8,
A100A12 calgranulin, and HMGB1 expression by high
glucose (Fig. 4C). The effect of GLO1 overexpression on
AP-1 binding to the promoters of S100A8, S100A12, and
HMGB1 are shown in Fig. 3D. AP-1 binding to these
promoters was determined using ChIP. High glucose in-
creased binding of this transcription factor to the three
RAGE ligand promoters, and GLO1 overexpression pre-
vented this increase.
Finally, expression of RAGE, S100A8, and HMGB1 was
evaluated in aortic endothelial cells isolated by laser
capture microdissection from nondiabetic mice, STZ dia-
betic mice, and STZ diabetic mice treated with the super-
oxide dismutase mimetic MnTBAP (Fig. 5). S100A12 was
not measured, since the S100A12 gene is not expressed in
rodents (21). To conﬁrm that laser capture microdissec-
tion had successfully isolated endothelial cells, mRNA
levels of vWF, an endothelial cell–speciﬁc marker; 
-actin,
a smooth muscle cell marker; and  actin, a control gene,
were measured (Fig. 5A and B). vWF mRNA was greatly
enriched in endothelial cells compared with SMCs,
whereas SMCs were greatly enriched in 
-actin compared
with endothelial cells.
Diabetes increased intracellular ROS, as determined by
3-nitrotyrosine levels, and MnTBAP treatment normalized
this (Fig. 5C). Representative Western blots for Fig. 5C are
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FIG. 4. Hyperglycemia-induced methylglyoxal increases binding of NFB to the RAGE promoter and binding of AP-1 to the S100A8, S10012, and
HMGB1 promoters. A: Conditionally immortalized HAECs were treated with low glucose (LG), high glucose (HG), or HG after transfection with
either scrambled oligonucleotides (LG and HG) or siRNA for p65 (HG/siP65) for 5 days, and the RAGE mRNA level was determined by qPCR (n 
3). B: Primary HAECs were treated with LG, HG, or HG after infections with either nontarget control or GLO1 adenovirus (HG/GLO1) for 5 days.
Chromatin immunoprecipitation was performed using the p65 antibody, and the RAGE promoter was ampliﬁed by qPCR (n  4). C: Conditionally
immortalized HAECs were treated with LG, HG, or HG after transfection with either scrambled oligonucleotides or siRNA for AP-1 (c-Jun)
(HG/siAP-1) for 5 days, and mRNA levels of S100A8, S10012, and HMGB1 were determined by qPCR (n  3). D: Primary HAECs were treated with
LG, HG, or HG after infections with either nontarget control or GLO1 adenovirus (HG/GLO1) for 5 days. Chromatin immunoprecipitation was
performed using c-Jun antibody, and the S100A8, 100A12, and HMGB1 promoters were ampliﬁed by qPCR (n  4). Values are shown as means 
SD. *P < 0.05 vs. LG group. (A high-quality color digital representation of this ﬁgure is available in the online issue.)
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modiﬁed protein were similarly increased by diabetes and
normalized by MnTBAP treatment (Fig. 5E). Representa-
tive Western blots for Fig. 5E are shown in Fig. 5F.
Diabetes increased RAGE mRNA levels by 1.8-fold,
S100A8 calgranulin mRNA levels by 1.7-fold, and HMGB1
mRNA levels by 2.4-fold (Fig. 5G). Treatment of diabetic
mice with the superoxide dismutase mimetic compound
MnTBAP normalized diabetic endothelial cell RAGE,
S100A8, and HMGB1 mRNA levels.
DISCUSSION
In the present study, we show that hyperglycemia-induced
ROS production by the mitochondrial electron transport
chain increases expression of RAGE and three high-afﬁnity
endogenous RAGE ligands—S100A8 calgranulin, S100A12
calgranulin, and HMGB1—that exhibit proinﬂammatory
effects in vitro at concentrations found at sites of inﬂam-
mation in vivo (9). This effect is mediated by ROS-induced
production of methylglyoxal, the major 
-oxoaldehyde
substrate of the enzyme glyoxalase 1. This increases
binding of NFB to the RAGE promoter and of AP-1 to the
S100A8, S100A12, and HMGB1 promoters. Diabetes also
increased expression of RAGE, S100A8, and HMGB1 in
aortic endothelial cells in vivo, and treatment of diabetic
mice with the superoxide dismutase mimetic MnTBAP
normalized each of these increases.
Much evidence supports a uniﬁed mechanism of hyper-
glycemia-induced cellular damage, in which intracellular
hyperglycemia develops in target cells of diabetic com-
plications, causing increased mitochondrial production
of ROS. The ROS cause strand breaks in nuclear DNA,
which activate the enzyme poly(ADP-ribose) polymerase
(PARP). PARP then modiﬁes GAPDH, thereby reducing its
activity. This decreased GAPDH activity activates the
polyol pathway, increases intracellular AGE formation,
activates PKC isoforms, increases NFB p65 transcription
and activity, and activates hexosamine pathway ﬂux
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FIG. 5. Treatment of diabetic mice with MnTBAP normalizes increased expression of RAGE, S100 calgranulins, and HMGB1. A: Aortic endothelial
cells (AEC) or smooth muscle cells (SMC) were isolated from either wild-type (WT) mice, STZ-induced diabetic mice (STZ), or STZ-diabetic mice
treated with MnTBAP (STZ/MnTBAP), using laser capture microdissection. mRNA levels for vWF (A) and -actin (B) were determined by qPCR
(n  3, *P < 0.05 vs. AEC group). C: 3-Nitrotyrosine content of aortic cells from the above mice was determined by Western blot (n  4, *P <
0.05 vs. CTL group). D: Representative blots for C. E: Methylglyoxal-modiﬁed protein content of aortic cells from the above mice was determined
by Western blot (n  4, *P < 0.05 vs. CTL group). F: Representative blots for E. G: Aortic endothelial cells were used for analysis of gene
expression by qPCR (n  3, *P < 0.05 vs. WT group). Values are shown as means  SD. (A high-quality color digital representation of this ﬁgure
is available in the online issue.)
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254 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.org(13,14,20). The data presented in the current study dem-
onstrate that increased expression of RAGE and of its
proinﬂammatory endogenous ligands are also a conse-
quence of hyperglycemia-induced ROS and thus constitute
another element of this unifying mechanism.
RAGE was originally identiﬁed by its ability to bind
advanced glycation end products. However, there is cur-
rently disagreement about the importance of AGE-modi-
ﬁed proteins as agonists of RAGE in vivo, because proteins
modiﬁed by AGEs to the extent necessary to bind RAGE
are unlikely to exist in physiological systems in vivo
(22–24). In contrast, S100/calgranulin proteins and high
mobility group-1 protein are present at sites of inﬂamma-
tion in vivo at concentrations that activate RAGE (9,15).
While modiﬁcation of the corepressor mSin3A by the
GLO1 substrate methylglyoxal has been shown to mediate
hyperglycemia-induced transcription of angiopoietin-2
(25), the speciﬁc methylglyoxal-modiﬁed protein(s) re-
sponsible for hyperglycemia-induced transcription of
RAGE and its ligands S100A8 calgranulin, S100A12 cal-
granulin, and HMGB1 remain to be determined. Regardless
of the speciﬁc proteins modiﬁed, however, the data pre-
sented here suggest that pharmacologic agents capable of
reducing methylglyoxal concentration in cells susceptible
to diabetic complications (14) may have a beneﬁcial effect
on the damaging consequences of nonphysiologic RAGE
activation (3).
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